The Influence of Low-Dose Dexmedetomidine on Recovery Times Following Sedation for Vitreoretinal Surgery: A Retrospective Cohort Study
Main finding · Mean discharge timeResult — go to the resultDifference −2.04 minutes 95% CI −5.71 to 1.65Authors' conclusion
A low-dose, bolus dexmedetomidine technique did not prolong the time to home discharge when administered for sedation during vitreoretinal surgery.
Study context
- Population
- Adults undergoing vitreoretinal surgery under RA and sedation at a high-volume ophthalmology specialty hospital, fiscal years 2020–2024
- Participants
- 6,180 vs 2,274
- Exposure
- Dexmedetomidine vs other medications for sedation
- Dexmedetomidinen = 6,180
- Without dexmedetomidinen = 2,274reference
- Outcome
- Discharge time (end of surgery until discharge home from phase II PACU)
Methodological detailssingle-centre, general linear models
- Single-centre
- General linear models
Main finding
Mean discharge time
Difference
−2.04 minutes
95% CI −5.71 to 1.65
P = 0.28
Dexmedetomidine vs Without dexmedetomidine
difference −2.04 minutes (95% CI −5.71 to 1.65); P = 0.28
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Dexmedetomidine dose (normalized for body weight and OR entry to end of surgery)
- 0.24 · mean · SD 0.20 · µg/kg/h
- Dexmedetomidine dose (normalized for body weight and OR entry to end of surgery) — Intermittent bolus doses without infusion
- 96.3%
Fraction of cases with dexmedetomidine sedation
- 2019
- <0.7%
- 2023
- 91.3%
Original publication
The Influence of Low-Dose Dexmedetomidine on Recovery Times Following Sedation for Vitreoretinal Surgery: A Retrospective Cohort Study. Anesth Analg. Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →